Dombernowsky P, Siegenthaler P, Somers R, Hansen H H
Eur J Cancer Clin Oncol. 1982 Jan;18(1):71-4. doi: 10.1016/0277-5379(82)90027-x.
A phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (amsacrine, m-AMSA) was carried out in previously treated patients with advanced ovarian carcinoma. The dose of amsacrine was 90 mg/m2 every 3 weeks in 34 patients having received prior extensive chemotherapy and/or radiotherapy, and 120 mg/m2 in 5 patients who had previously only received moderate amounts of chemotherapy. Among patients evaluable for response the median number of courses was 3 (range 2-17). Two patients (5%) experienced complete response for 15+ months. Leucopenia was the most frequent toxic effect. WBC nadir was 2700/mm3 (range 1000-7300). Other toxic effects were of lesser significance and included thrombocytopenia, anemia, nausea and vomiting. It is concluded that amsacrine has only marginal activity in patients with previously treated ovarian carcinoma.
对4'-(9-吖啶基氨基)甲磺基间茴香胺（安吖啶，m-AMSA）进行了一项II期研究，研究对象为先前接受过治疗的晚期卵巢癌患者。34例先前接受过广泛化疗和/或放疗的患者，安吖啶剂量为每3周90mg/m²；5例先前仅接受过中等剂量化疗的患者，安吖啶剂量为120mg/m²。在可评估反应的患者中，疗程中位数为3（范围2 - 17）。2例患者（5%）出现持续15个月以上的完全缓解。白细胞减少是最常见的毒性反应。白细胞最低点为2700/mm³（范围1000 - 7300）。其他毒性反应意义较小，包括血小板减少、贫血、恶心和呕吐。结论是，安吖啶在先前接受过治疗的卵巢癌患者中仅具有边缘活性。
